Research Progress of Intestinal Microecology in Spontaneous Bacterial Peritonitis in Liver Cirrhosis
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i2.4062
Abstract
Spontaneous bacterial peritonitis (SBP) is a common and serious complication in patients with cirrhosis and ascites. This disease is caused by infection of the abdominal cavity by pathogenic bacteria through the intestinal tract, blood or lymphatic system, and it is one of the important causes of death in patients with end-stage liver disease. The main pathogenesis is bacterial translocation. This article aims to review the research progress of intestinal microecology in the occurrence, progression and treatment of SBP.
Keywords
Intestinal microecology; Liver cirrhosis; Spontaneous bacterial peritonitis.
Full Text
PDF - Viewed/Downloaded: 2 TimesReferences
[1] X. Xu et al., Chinese guidelines on the management of ascites in cirrhosis : Chinese Society of Hepatology, Chinese Medical Association. Hepatol Int 18, 1071-1089 (2024).
[2] Y. Chen, J. Zhou, L. Wang, Role and Mechanism of Gut Microbiota in Human Disease. Front Cell Infect Microbiol 11, 625913 (2021).
[3]S. P. Sharma et al., Gut microbiome and metabolome signatures in liver cirrhosis-related complications. Clin Mol Hepatol 30, 845-862 (2024).
[4]I. Gómez-Hurtado, J. Such, R. Francés, Microbiome and bacterial translocation in cirrhosis. Gastroenterol Hepatol 39, 687-696 (2016).
[5]L. Verbeke, F. Nevens, W. Laleman, Steroidal or non-steroidal FXR agonists - Is that the question? J Hepatol 66, 680-681 (2017).
[6]S. Fiorucci, E. Distrutti, Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension. Pharmacol Res 111, 749-756 (2016).
[7]K. Ray, Therapy: Experimental portal hypertension - pinning hopes on FXR agonists? Nat Rev Gastroenterol Hepatol 14, 68 (2017).
[8]L. Verbeke et al., Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59, 2286-2298 (2014).
[9]M. Sorribas et al., FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. J Hepatol 71, 1126-1140 (2019).
[10]M. Haderer et al., Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases. Gut 71, 580-592 (2022).
[11]H. K. H. Keryakos, A. A. Mohammed, A. M. Higazi, E. A. M. Mahmoud, Z. M. Saad, Serum and ascitic fluid interleukin-17 in spontaneous bacterial peritonitis in Egyptian patients with HCV-related liver cirrhosis. Curr Res Transl Med 68, 237-243 (2020).
[12]S. W. Biggins et al., Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 74, 1014-1048 (2021).
[13]M. A. Hanouneh et al., The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 46, 709-715 (2012).
[14]F. Kamal et al., Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 29, 1109-1117 (2017).
[15]A. Goel, U. Rahim, L. H. Nguyen, C. Stave, M. H. Nguyen, Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharmacol Ther 46, 1029-1036 (2017).
[16]H. Soni et al., Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis. Hepatol Int 14, 399-413 (2020).
[17]O. Komolafe et al., Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 1, Cd013125 (2020).
[2] Y. Chen, J. Zhou, L. Wang, Role and Mechanism of Gut Microbiota in Human Disease. Front Cell Infect Microbiol 11, 625913 (2021).
[3]S. P. Sharma et al., Gut microbiome and metabolome signatures in liver cirrhosis-related complications. Clin Mol Hepatol 30, 845-862 (2024).
[4]I. Gómez-Hurtado, J. Such, R. Francés, Microbiome and bacterial translocation in cirrhosis. Gastroenterol Hepatol 39, 687-696 (2016).
[5]L. Verbeke, F. Nevens, W. Laleman, Steroidal or non-steroidal FXR agonists - Is that the question? J Hepatol 66, 680-681 (2017).
[6]S. Fiorucci, E. Distrutti, Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension. Pharmacol Res 111, 749-756 (2016).
[7]K. Ray, Therapy: Experimental portal hypertension - pinning hopes on FXR agonists? Nat Rev Gastroenterol Hepatol 14, 68 (2017).
[8]L. Verbeke et al., Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59, 2286-2298 (2014).
[9]M. Sorribas et al., FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. J Hepatol 71, 1126-1140 (2019).
[10]M. Haderer et al., Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases. Gut 71, 580-592 (2022).
[11]H. K. H. Keryakos, A. A. Mohammed, A. M. Higazi, E. A. M. Mahmoud, Z. M. Saad, Serum and ascitic fluid interleukin-17 in spontaneous bacterial peritonitis in Egyptian patients with HCV-related liver cirrhosis. Curr Res Transl Med 68, 237-243 (2020).
[12]S. W. Biggins et al., Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 74, 1014-1048 (2021).
[13]M. A. Hanouneh et al., The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 46, 709-715 (2012).
[14]F. Kamal et al., Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 29, 1109-1117 (2017).
[15]A. Goel, U. Rahim, L. H. Nguyen, C. Stave, M. H. Nguyen, Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharmacol Ther 46, 1029-1036 (2017).
[16]H. Soni et al., Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis. Hepatol Int 14, 399-413 (2020).
[17]O. Komolafe et al., Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 1, Cd013125 (2020).
Copyright © 2025 Chunli Yang, Xiaoping Tan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License